These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 23788689)

  • 1. Sclerostin: Another vascular calcification inhibitor?
    Claes KJ; Viaene L; Heye S; Meijers B; d'Haese P; Evenepoel P
    J Clin Endocrinol Metab; 2013 Aug; 98(8):3221-8. PubMed ID: 23788689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum sclerostin: the missing link in the bone-vessel cross-talk in hemodialysis patients?
    Pelletier S; Confavreux CB; Haesebaert J; Guebre-Egziabher F; Bacchetta J; Carlier MC; Chardon L; Laville M; Chapurlat R; London GM; Lafage-Proust MH; Fouque D
    Osteoporos Int; 2015 Aug; 26(8):2165-74. PubMed ID: 25910747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationships between serum sclerostin, bone mineral density, and vascular calcification in rheumatoid arthritis.
    Paccou J; Mentaverri R; Renard C; Liabeuf S; Fardellone P; Massy ZA; Brazier M; Kamel S
    J Clin Endocrinol Metab; 2014 Dec; 99(12):4740-8. PubMed ID: 25222755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sclerostin Serum Levels and Vascular Calcification Progression in Prevalent Renal Transplant Recipients.
    Evenepoel P; Goffin E; Meijers B; Kanaan N; Bammens B; Coche E; Claes K; Jadoul M
    J Clin Endocrinol Metab; 2015 Dec; 100(12):4669-76. PubMed ID: 26505822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications.
    Morena M; Jaussent I; Dupuy AM; Bargnoux AS; Kuster N; Chenine L; Leray-Moragues H; Klouche K; Vernhet H; Canaud B; Cristol JP
    Nephrol Dial Transplant; 2015 Aug; 30(8):1345-56. PubMed ID: 25854266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum sclerostin values are associated with abdominal aortic calcification and predict cardiovascular events in patients with chronic kidney disease stages 3-5D.
    Wang XR; Yuan L; Zhang JJ; Hao L; Wang DG
    Nephrology (Carlton); 2017 Apr; 22(4):286-292. PubMed ID: 27165564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sclerostin as a new key factor in vascular calcification in chronic kidney disease stages 3 and 4.
    Lv W; Guan L; Zhang Y; Yu S; Cao B; Ji Y
    Int Urol Nephrol; 2016 Dec; 48(12):2043-2050. PubMed ID: 27465794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients.
    Kanbay M; Siriopol D; Saglam M; Kurt YG; Gok M; Cetinkaya H; Karaman M; Unal HU; Oguz Y; Sari S; Eyileten T; Goldsmith D; Vural A; Veisa G; Covic A; Yilmaz MI
    J Clin Endocrinol Metab; 2014 Oct; 99(10):E1854-61. PubMed ID: 25057883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Serum Sclerostin Levels Are Associated with a Better Outcome in Haemodialysis Patients.
    Jean G; Chazot C; Bresson E; Zaoui E; Cavalier E
    Nephron; 2016; 132(3):181-90. PubMed ID: 26890570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal elimination of sclerostin increases with declining kidney function.
    Cejka D; Marculescu R; Kozakowski N; Plischke M; Reiter T; Gessl A; Haas M
    J Clin Endocrinol Metab; 2014 Jan; 99(1):248-55. PubMed ID: 24187403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness.
    Thambiah S; Roplekar R; Manghat P; Fogelman I; Fraser WD; Goldsmith D; Hampson G
    Calcif Tissue Int; 2012 Jun; 90(6):473-80. PubMed ID: 22527202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating Wnt/β-catenin signalling inhibitors and uraemic vascular calcifications.
    Yang CY; Chang ZF; Chau YP; Chen A; Yang WC; Yang AH; Lee OK
    Nephrol Dial Transplant; 2015 Aug; 30(8):1356-63. PubMed ID: 25817223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Sclerostin: a new biomarker of interest in nephrology].
    Pelletier S; Jean G; Fouque D;
    Ann Biol Clin (Paris); 2015; 73(3):305-13. PubMed ID: 26069067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and biological determinants of sclerostin plasma concentration in hemodialysis patients.
    Delanaye P; Krzesinski JM; Warling X; Moonen M; Smelten N; Médart L; Bruyère O; Reginster JY; Pottel H; Cavalier E
    Nephron Clin Pract; 2014; 128(1-2):127-34. PubMed ID: 25377055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study.
    Drechsler C; Evenepoel P; Vervloet MG; Wanner C; Ketteler M; Marx N; Floege J; Dekker FW; Brandenburg VM;
    Nephrol Dial Transplant; 2015 Feb; 30(2):288-93. PubMed ID: 25248363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sclerostin levels associated with inhibition of the Wnt/β-catenin signaling and reduced bone turnover in type 2 diabetes mellitus.
    Gaudio A; Privitera F; Battaglia K; Torrisi V; Sidoti MH; Pulvirenti I; Canzonieri E; Tringali G; Fiore CE
    J Clin Endocrinol Metab; 2012 Oct; 97(10):3744-50. PubMed ID: 22855334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease].
    Milovanova LY; Milovanov YS; Kudryavtseva DV; Markina MM; Milovanova SY; Kozlovskaya LV; Lebedeva MV; Beketov VD; Moiseev SV; Mukhin NA; Fomin VV; Svistunov AA
    Ter Arkh; 2015; 87(6):10-16. PubMed ID: 26281189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women.
    Hampson G; Edwards S; Conroy S; Blake GM; Fogelman I; Frost ML
    Bone; 2013 Sep; 56(1):42-7. PubMed ID: 23702386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of bone-derived biomarkers with vascular calcification in chronic hemodialysis patients.
    Lee YT; Ng HY; Chiu TT; Li LC; Pei SN; Kuo WH; Lee CT
    Clin Chim Acta; 2016 Jan; 452():38-43. PubMed ID: 26522655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis?
    Viaene L; Behets GJ; Claes K; Meijers B; Blocki F; Brandenburg V; Evenepoel P; D'Haese PC
    Nephrol Dial Transplant; 2013 Dec; 28(12):3024-30. PubMed ID: 23605174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.